Literature DB >> 20642709

The prevention of deep venous thrombosis in physically restrained patients with schizophrenia.

M De Hert1, G Einfinger, E Scherpenberg, M Wampers, J Peuskens.   

Abstract

BACKGROUND: Physical restraint and seclusion are associated with several risks. Antipsychotic drug use increases this risk.
OBJECTIVE: To evaluate whether the risk of thromboembolism in physical restraint and seclusion of patients with psychosis, treated with antipsychotic medication, was considered by taking preventive measures.
METHOD: Anonymous data on all consecutively admitted patients with schizophrenia, treated with antipsychotic medication, between 2002 and 2009, were analysed. Diagnostic information and data about seclusion procedures and medication were collected. Preventive measures of thromboembolism in patients in physical restraint were assessed by reviewing case notes and the medication prescribed at the time of seclusion.
RESULTS: Seclusion of patients with psychosis is common. Out of 679 identified patients, 170 had been secluded (472 events). Physical restraint use was not a rare event (N seclusions with restraint use 296, 62.7%). Pharmacological preventive measures (use of heparine drugs) were taken frequently to prevent deep vein thrombosis (DVT) by physical restraint or isolation. Sixty-five (38.2%) out of 170 secluded patients, including a majority of patients who had been under physical restraint, had been administered anticoagulants at the time of seclusion. No cases of DVT occurred.
CONCLUSIONS: Preventive measures were routinely administered in clinical practice and were effective in the prevention of DVT. For a clinical setting, it is important to establish a clear and detailed management plan on seclusion and fixation taken into account in all possible risks of physical restraint.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20642709     DOI: 10.1111/j.1742-1241.2010.02380.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  8 in total

Review 1.  Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management.

Authors:  Anna K Jönsson; Olav Spigset; Staffan Hägg
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

Review 2.  Prevalence and correlates of seclusion and restraint use in children and adolescents: a systematic review.

Authors:  Marc De Hert; Nele Dirix; Hella Demunter; Christoph U Correll
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-02-05       Impact factor: 4.785

Review 3.  Management of Violence and Aggression in Emergency Environment; a Narrative Review of 200 Related Articles.

Authors:  Maryam Ziaei; Ali Massoudifar; Ali Rajabpour-Sanati; Ali-Mohammad Pourbagher-Shahri; Ali Abdolrazaghnejad
Journal:  Adv J Emerg Med       Date:  2018-11-29

4.  Venous thromboembolism prophylaxis in mental healthcare: do the benefits outweigh the risks?

Authors:  Rashmi Patel
Journal:  BJPsych Bull       Date:  2015-04

Review 5.  Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review.

Authors:  Xin Yu; Christoph U Correll; Yu-Tao Xiang; Yifeng Xu; Jizhong Huang; Fude Yang; Gang Wang; Tianmei Si; John M Kane; Prakash Masand
Journal:  Shanghai Arch Psychiatry       Date:  2016-10-25

6.  Case report: Chlorpromazine and deep venous thrombosis.

Authors:  Matthew Joseph Reed; Sean Comeau; Todd R Wojtanowicz; Bharat Reddy Sampathi; Sofia Penev; Robert Bota
Journal:  Ment Illn       Date:  2019-11-04

Review 7.  Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change.

Authors:  Bruno Pacciardi; Alfredo Calcedo; Thomas Messer
Journal:  Drugs R D       Date:  2019-03

8.  Introduction of a Venous Thromboembolism Prophylaxis Protocol for Older Adult Psychiatric Patients.

Authors:  Anna Croxford; Adam Clare; Kathleen McCurdy
Journal:  BMJ Qual Improv Rep       Date:  2015-05-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.